Oral and GI Mucositis — Part 1: Pathobiology, Grading Scales, and Risk Factors

1. Pathobiology of Mucositis

1.1 Overview

Mucositis was historically viewed as a simple, inevitable consequence of cytotoxic damage to rapidly dividing mucosal epithelial cells. Contemporary understanding, based on the five-phase biological model, reveals mucositis to be a far more complex process involving multiple biological pathways, the submucosal and mucosal microenvironment, and intricate interactions between tissues, the immune system, and the oral/gastrointestinal microbiome.^{1 2}

The mucosal epithelium of the oral cavity turns over approximately every 7–14 days, making it highly susceptible to the effects of cytotoxic therapies that target rapidly dividing cells. However, the clinical manifestations of mucositis result from injury to all components of the mucosa — epithelium, connective tissue, vasculature, and innervation — not epithelial cells alone.

1.2 The Five-Phase Pathobiology Model

The following model describes the sequential and overlapping biological events that lead to clinical mucositis.^{1 2}

Phase 1: Initiation (Day 0–2)

Chemotherapy and/or radiation therapy cause direct cellular injury through:

• DNA strand breaks in basal epithelial cells and submucosal cells
• Generation of reactive oxygen species (ROS) from both direct drug effects and radiation-induced water radiolysis
• Direct endothelial damage in the submucosal vasculature

ROS serve as the key initial trigger, activating downstream signaling cascades even before any clinically visible mucosal changes occur. At this stage, the mucosa appears normal on clinical examination.

Phase 2: Primary Damage Response and Messaging (Day 2–5)

ROS and direct DNA damage activate multiple signaling pathways:

• Nuclear factor kappa-B (NF-kB) — a master transcription factor that is activated by ROS and DNA damage and upregulates the production of pro-inflammatory cytokines
• Tumor necrosis factor alpha (TNF-alpha) — amplifies NF-kB activation in a positive feedback loop and causes direct tissue injury
• Interleukin-1-beta (IL-1-beta) and interleukin-6 (IL-6) — further amplify inflammation
• Mitogen-activated protein kinase (MAPK) pathway activation
• Ceramide pathway activation leading to apoptosis
• Cyclooxygenase-2 (COX-2) upregulation

These pathways collectively cause connective tissue injury, increased vascular permeability, submucosal edema, and initiation of epithelial apoptosis. The mucosa may appear erythematous at this stage (corresponding to Grade 1 mucositis).

Phase 3: Signal Amplification (Day 5–10)

Positive feedback loops intensify the injury:

• TNF-alpha further activates NF-kB, which produces additional TNF-alpha, IL-1-beta, and IL-6
• Matrix metalloproteinases (MMPs) are activated, causing extracellular matrix degradation
• The fibronectin breakdown products themselves become pro-inflammatory signals
• Submucosal macrophages amplify the inflammatory cascade
• Ceramide-mediated apoptosis accelerates epithelial cell death

The disproportionate tissue injury relative to the initial insult is a hallmark of this phase and explains why mucositis severity often exceeds what would be predicted from direct cytotoxic cell kill alone.

Phase 4: Ulceration and Bacterial Colonization (Day 10–15)

This is the most clinically significant and symptomatic phase:

• Full-thickness epithelial loss results in deep ulceration exposing the underlying connective tissue
• Ulcers become colonized by oral bacteria (gram-negative organisms, anaerobes)
• Bacterial cell wall products (e.g., lipopolysaccharide, LPS; muramyl dipeptide, MDP) penetrate the submucosa and activate macrophages via toll-like receptors (TLRs)
• This bacterial-driven secondary activation produces additional waves of pro-inflammatory cytokines
• Pseudomembrane formation overlying ulcerated areas
• Pain is severe, often requiring opioid analgesia
• In neutropenic patients, the ulcerated mucosa serves as a portal of entry for systemic bacteremia and sepsis

The ulcerative phase typically coincides with the nadir of chemotherapy-induced neutropenia, creating a period of maximal risk.

Phase 5: Healing (Day 15–21+)

Healing occurs through:

• Extracellular matrix signaling stimulating epithelial cell migration and proliferation from wound margins
• Re-establishment of the mucosal barrier
• Restoration of normal oral flora
• Resolution of inflammatory infiltrate
• Peripheral blood count recovery (in the context of chemotherapy) facilitates immune-mediated tissue repair

Healing is generally complete without scarring in the oral mucosa. In the GI tract, healing may be less complete and may involve structural changes. Repeated cycles of injury (as with multi-cycle chemotherapy or fractionated radiation) can cause cumulative damage that impairs the healing process and accelerates subsequent episodes.

1.3 GI Mucositis Pathobiology

The same five-phase model applies to the gastrointestinal mucosa, with additional considerations:³

• Crypt cell damage in the small intestine leads to villous atrophy, decreased absorptive surface area, and secretory diarrhea
• Disruption of tight junctions between enterocytes increases mucosal permeability
• Loss of brush border enzymes (e.g., lactase, sucrase) causes malabsorption
• Altered intestinal motility — both increased transit (from prostaglandin release) and dysmotility
• Translocation of gut bacteria across the damaged mucosal barrier, which is a major contributor to febrile neutropenia and gram-negative sepsis
• The intestinal microbiome undergoes significant dysbiosis, with loss of commensal organisms and overgrowth of pathogenic species

2. Grading Scales for Mucositis

Accurate and reproducible assessment of mucositis severity is essential for clinical management, treatment decision-making, dose modification, clinical trial enrollment, and outcomes research. Several validated grading scales exist, each with specific applications.^{4 5}

2.1 WHO Oral Toxicity Scale

The World Health Organization (WHO) scale is the most widely used grading system in both clinical practice and research. It integrates both objective findings and functional assessment.⁴

Advantages: Simple, widely recognized, combines objective and subjective parameters, allows comparison across studies.

Limitations: Grades 3 and 4 are based primarily on dietary ability, which may be affected by factors other than mucositis (e.g., nausea, odynophagia from esophagitis). Limited anatomic specificity. Inter-rater variability exists.

2.2 NCI Common Terminology Criteria for Adverse Events (CTCAE) — Mucositis

The NCI CTCAE (currently version 5.0) provides separate grading criteria for oral mucositis and GI mucositis and is the standard scale for adverse event reporting in clinical trials.⁵

Oral Mucositis (CTCAE v5.0)

Lower GI — Diarrhea (CTCAE v5.0)

Colitis (CTCAE v5.0)

2.3 Oral Mucositis Assessment Scale (OMAS)

The OMAS is a validated research instrument that provides a more granular, site-specific assessment. It evaluates ulceration/pseudomembrane and erythema at nine specific oral anatomic sites.⁶

Anatomic Sites Assessed

1. Upper lip
2. Lower lip
3. Right cheek
4. Left cheek
5. Right ventral and lateral tongue
6. Left ventral and lateral tongue
7. Floor of mouth
8. Soft palate / fauces
9. Hard palate

Scoring Components

Ulceration / Pseudomembrane (each site scored 0–3):

Erythema (each site scored 0–2):

Scoring: The mean ulceration score and the mean erythema score across all nine sites are calculated separately. The combined OMAS score is the sum of the mean ulceration and mean erythema scores. A higher score indicates more severe mucositis.

Advantages: High inter-rater reliability; sensitive to change; site-specific assessment allows identification of patterns (e.g., non-keratinized mucosa is preferentially affected by chemotherapy). Well validated for clinical trials.

Limitations: More time-consuming than the WHO scale; requires trained assessors; does not capture functional impact (pain, dietary ability) directly.

2.4 Additional Assessment Tools

3. Risk Factors for Mucositis

3.1 Treatment-Related Risk Factors

3.1.1 Chemotherapy Agents

The mucositis risk varies substantially by agent, dose, schedule, and route of administration.^{7 8}

High risk (oral mucositis incidence >40% at standard doses):

Moderate risk (oral mucositis incidence 10–40%):

Targeted and immunotherapy agents with mucositis risk:

3.1.2 Radiation Therapy

Radiation-induced mucositis is determined by the anatomic site, total dose, fractionation schedule, and concurrent systemic therapy.⁹

Key radiation thresholds:

• Oral mucositis onset: Typically after 10–15 Gy (end of week 1–2 of conventional fractionation)
• Peak severity: Usually at 30–50 Gy (weeks 3–5); nearly all patients receiving >50 Gy to oral mucosal surfaces develop Grade 3–4 mucositis
• Salivary gland function impairment: Mean dose >26 Gy to the parotid glands results in significant xerostomia, which exacerbates mucositis and impairs healing
• GI mucositis (pelvic radiation): Onset typically at 20–30 Gy; small bowel and rectum are the most susceptible

3.1.3 Hematopoietic Stem Cell Transplant Conditioning

3.2 Patient-Related Risk Factors

4. Pre-Treatment Dental and Oral Assessment

4.1 Rationale

Pre-treatment oral assessment and dental stabilization are recommended for all patients about to begin cancer therapy with mucositis risk. The goals are to:^{10 11}

1. Identify and treat pre-existing oral infections (dental caries, periodontal disease, periapical pathology) that can become fulminant during immunosuppression
2. Remove sources of mucosal trauma (sharp teeth, ill-fitting prostheses, orthodontic appliances)
3. Establish a baseline oral assessment for comparison during treatment
4. Optimize oral hygiene and educate the patient on oral self-care during cancer therapy
5. Prevent osteoradionecrosis in patients who will receive head and neck radiation

4.2 Recommended Pre-Treatment Dental Protocol

4.3 Special Considerations for Head and Neck Radiation

Patients receiving radiation therapy involving the mandible or maxilla require particular attention to prevent osteoradionecrosis (ORN):

• All teeth with questionable prognosis in or near the radiation field should be extracted prior to treatment
• Extractions should be performed with minimal trauma and primary closure
• A minimum healing period of 14–21 days (ideally longer) should precede the start of radiation
• Hyperbaric oxygen therapy before dental extraction in the irradiated field is controversial; current evidence does not support routine use, but it may be considered in high-risk situations¹²
• Post-radiation dental extractions should be avoided whenever possible; if necessary, antibiotic prophylaxis, atraumatic technique, and close follow-up are mandatory

References